Prediction of Response to Immune Checkpoint Inhibito Early-Time-Point¹⁸F-FDG PET/CT Imaging

Journal of Nuclear Medicine

58, 1421-1428

DOI: 10.2967/jnumed.116.188839

Citation Report

#	Article	IF	Citations
1	Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. Expert Opinion on Pharmacotherapy, 2017, 18, 1477-1490.	0.9	24
2	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2310-2325.	3.3	46
3	The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1289-1296.	3.3	90
4	Immunotherapy and the role of imaging. Cancer, 2018, 124, 2906-2922.	2.0	63
5	In Vivo Molecular Imaging for Biomedical Analysis and Therapies. Analytical Sciences, 2018, 34, 273-277.	0.8	14
6	Imaging melanoma: when and why. A proposal for a modern approach. Clinical and Translational Imaging, 2018, 6, 123-134.	1.1	0
7	Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma. Lung Cancer, 2018, 119, 71-77.	0.9	46
8	18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 95-101.	3.3	46
9	Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 376-383.	3.3	160
10	T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. Theranostics, 2018, 8, 6070-6087.	4.6	28
11	Role of noninvasive molecular imaging in determining response. Advances in Radiation Oncology, 2018, 3, 534-547.	0.6	25
12	AntiÂPD-1 treatment increases [18F]FDG uptake by cancer cells in a mouse B16F10 melanoma model. EJNMMI Research, 2018, 8, 82.	1.1	18
13	The Immunoimaging Toolbox. Journal of Nuclear Medicine, 2018, 59, 1174-1182.	2.8	68
14	Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST. Annals of Nuclear Medicine, 2018, 32, 453-462.	1.2	6
15	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatmentâ€"A Review From the Melanoma Perspective and Beyond. Frontiers in Immunology, 2018, 9, 1474.	2.2	174
16	Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity. Immunotherapy, 2018, 10, 797-805.	1.0	20
17	Magnetic resonance imaging of cancer metabolism with hyperpolarized 13C-labeled cell metabolites. Current Opinion in Chemical Biology, 2018, 45, 187-194.	2.8	40
18	FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Annals of Oncology, 2018, 29, 2115-2120.	0.6	131

#	Article	IF	Citations
19	Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. Cancer Immunology, Immunotherapy, 2018, 67, 1261-1270.	2.0	22
20	Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PETâ€“CT. Cancer Immunology, Immunotherapy, 2019, 68, 813-822.	2.0	51
21	¹⁸F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors. Leukemia and Lymphoma, 2019, 60, 367-375.	0.6	27
22	Imaging Melanoma. , 2019, , 557-581.		0
23	Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction. Cancer Medicine, 2019, 8, 5399-5413.	1.3	15
24	Immunotherapy and 18F-FDG PET/CT: standardised procedures are needed. Clinical and Translational Imaging, 2019, 7, 313-315.	1.1	8
25	Immune Checkpoint Inhibitor Therapyâ€“related Pneumonitis: Patterns and Management. Radiographics, 2019, 39, 1923-1937.	1.4	109
26	Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patientâ€™s Bedside to Evaluation in Preclinical Models. Toxins, 2019, 11, 20.	1.5	37
27	Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Research, 2019, 9, 8.	1.1	121
28	Very Early Response Evaluation by PET/MR in Patients with Lung Cancerâ€”Timing and Feasibility. Diagnostics, 2019, 9, 35.	1.3	5
29	Tumor Heterogeneity on FDG PET/CT and Immunotherapy: An Imaging Biomarker for Predicting Treatment Response in Patients With Metastatic Melanoma. American Journal of Roentgenology, 2019, 212, 1318-1326.	1.0	27
30	Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response. Radiology Imaging Cancer, 2019, 1, e190031.	0.7	22
31	Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Nonâ€“Small Cell Lung Cancer. Clinical Nuclear Medicine, 2019, 44, 535-543.	0.7	48
32	Nivolumab-Induced Pneumonitis in Patient With Metastatic Melanoma Showing Complete Remission on 18F-FDG PET/CT. Clinical Nuclear Medicine, 2019, 44, 806-807.	0.7	10
33	18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Research, 2019, 29, 178-186.	0.6	43
34	Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. Melanoma Research, 2019, 29, 453-464.	0.6	26
35	Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. Medicine (United States), 2019, 98, e16417.	0.4	28
36	¹⁸F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. Journal of Nuclear Medicine, 2019, 60, 335-341.	2.8	123

#	Article	IF	Citations
37	FDG PET/CT for assessing tumour response to immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 238-250.	3.3	194
38	18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 178-184.	3.3	11
40	PET/Computed Tomography in Treatment Response Assessment in Cancer. PET Clinics, 2020, 15, 101-123.	1.5	8
41	Image Guided Dermatologic Treatments. , 2020, , .		4
44	Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?. Journal of Nuclear Medicine, 2020, 61, 1137-1144.	2.8	9
45	Imaging of Novel Oncologic Treatments in Lung Cancer Part 1. Journal of Thoracic Imaging, 2020, 35, 26-36.	0.8	4
46	18F-Fludeoxyglucose PET/Computed Tomography for Assessing Tumor Response to Immunotherapy and Detecting Immune-Related Side Effects. PET Clinics, 2020, 15, 1-10.	1.5	20
47	Molecular imaging biomarkers for immune checkpoint inhibitor therapy. Theranostics, 2020, 10, 1708-1718.	4.6	68
48	Comparison Between ¹⁸F-FDG PETâ€“Based and CT-Based Criteria in Nonâ€“Small Cell Lung Cancer Patients Treated with Nivolumab. Journal of Nuclear Medicine, 2020, 61, 990-998.	2.8	44
49	Preclinical PERCIST and 25% of SUV_{max} Threshold: Precision Imaging of Response to Therapy in Co-clinical ¹⁸F-FDG PET Imaging of Triple-Negative Breast Cancer Patientâ€“Derived Tumor Xenografts. Journal of Nuclear Medicine, 2020, 61, 842-849.	2.8	12
50	18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1158-1167.	3.3	72
51	Criteria of metabolic response to immunotherapy. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2020, 39, 51-56.	0.1	0
52	Application and Prospects of Molecular Imaging in Immunotherapy . Cancer Management and Research, 2020, Volume 12, 9389-9403.	0.9	8
53	Assessing Immunotherapy with Functional and Molecular Imaging and Radiomics. Radiographics, 2020, 40, 1987-2010.	1.4	22
54	The Interaction of Genomics, Molecular Imaging, and Therapy in Gastrointestinal Tumors. Seminars in Nuclear Medicine, 2020, 50, 471-483.	2.5	2
55	Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review. Critical Reviews in Oncology/Hematology, 2020, 153, 103044.	2.0	29
56	Immune-Directed Molecular Imaging Biomarkers. Seminars in Nuclear Medicine, 2020, 50, 584-603.	2.5	3
57	Molecular imaging in immuno-oncology: current status and translational perspectives. Expert Review of Molecular Diagnostics, 2020, 20, 1199-1211.	1.5	8

#	Article	IF	Citations
58	Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma. Case Reports in Urology, 2020, 2020, 1-6.	0.1	3
59	Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches. International Journal of Radiation Oncology Biology Physics, 2020, 108, 242-257.	0.4	8
60	Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1. Frontiers in Oncology, 2020, 10, 1090.	1.3	20
61	Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology. Medicina (Lithuania), 2020, 56, 373.	0.8	8
62	Is there a link between very early changes of primary and secondary lymphoid organs in ¹⁸F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?. , 2020, 8, e000656.		21
63	Reciprocal change in Glucose metabolism of Cancer and Immune Cells mediated by different Glucose Transporters predicts Immunotherapy response. Theranostics, 2020, 10, 9579-9590.	4.6	25
64	Impact of PET/CT for Assessing Response to Immunotherapyâ€"A Clinical Perspective. Journal of Clinical Medicine, 2020, 9, 3483.	1.0	26
65	Functional Imaging of Immunotherapy: Response Criteria, Imaging Characteristics, and Novel Immunoimaging of Advanced Malignancies. Current Radiology Reports, 2020, 8, 1.	0.4	0
66	Moderne Aspekte der Immuntherapie mit Checkpoint-Inhibitoren bei Melanom. Karger Kompass Dermatologie, 2020, 8, 92-101.	0.0	0
67	Predictive value of integrated18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer. , 2020, 8, e000349.		19
68	ImmunoPET: Concept, Design, and Applications. Chemical Reviews, 2020, 120, 3787-3851.	23.0	263
69	18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art. Current Radiopharmaceuticals, 2020, 13, 228-237.	0.3	17
70	FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. Seminars in Nuclear Medicine, 2020, 50, 518-531.	2.5	25
71	PET/CT and the Response to Immunotherapy in Lung Cancer. Current Radiopharmaceuticals, 2020, 13, 177-184.	0.3	17
72	When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?. American Journal of Clinical Dermatology, 2020, 21, 313-321.	3.3	3
73	Molecular imaging and immunotherapy. International Journal of Biological Markers, 2020, 35, 37-41.	0.7	2
74	Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors. Clinical Nuclear Medicine, 2020, 45, 187-194.	0.7	31
75	Immunotherapy-related adverse effects on ¹⁸F-FDG PET/CT imaging. British Journal of Radiology, 2020, 93, 20190832.	1.0	33

#	Article	IF	Citations
76	Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications. Cancers, 2020, 12, 371.	1.7	49
77	Criterios de respuesta metabÃ³lica a la inmunoterapia. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2020, 39, 51-56.	0.0	0
78	FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2776-2786.	3.3	42
79	Metastatic melanoma: can FDG-PET predict success of anti-PD-1 therapy and help determine when it can be discontinued?. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2227-2232.	3.3	8
80	Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2787-2795.	3.3	21
81	Predictive value of FDGâ€PET imaging for relapse in metastatic melanoma patients treated with immunotherapy. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2261-2267.	1.3	6
82	Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. Clinical Cancer Research, 2020, 26, 4414-4425.	3.2	70
83	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. International Journal of Molecular Sciences, 2020, 21, 2367.	1.8	34
84	A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment. Clinical and Translational Oncology, 2021, 23, 434-449.	1.2	6
85	The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 428-448.	3.3	60
86	Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism. Radiographics, 2021, 41, 120-143.	1.4	27
88	Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. Advanced Therapeutics, 2021, 4, 2000147.	1.6	2
89	Treatment Response Evaluation: Science and Practice. , 2021, , 3-9.		0
90	[18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors. Oncology Research and Treatment, 2021, 44, 400-407.	0.8	13
91	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. , 2021, , 83-99.		0
92	Reporting Post-Therapy Scans. , 2021, , 119-128.		0
93	Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. Journal of Translational Medicine, 2021, 19, 70.	1.8	5
94	Inmunoterapia, cÃ¡ncer y PET. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 123-135.	0.0	0

#	Article	IF	Citations
95	PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLCâ€"current state and future directions. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3975-3989.	3.3	25
96	Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors. Cancers, 2021, 13, 1019.	1.7	12
97	Apport de la TEP-TDM au 18F-FDG chez des patients avec cancer bronchique non Ã petites cellules ou mÃ©lanome mÃ©tastatique traitÃ©s par immunothÃ©rapie. Medecine Nucleaire, 2021, 45, 59-69.	0.2	0
98	Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT. Cancers, 2021, 13, 1098.	1.7	7
99	Immunotherapy, cancer and PET. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 123-135.	0.1	1
100	Radiomics in immuno-oncology. Immuno-Oncology Technology, 2021, 9, 100028.	0.2	2
101	Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade. Cancer Research, 2021, 81, 3693-3705.	0.4	15
102	Radiological assessment of response and adverse events associated with novel systemic oncological therapies. Clinical Radiology, 2021, 76, 247-261.	0.5	0
103	PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology. International Journal of Molecular Sciences, 2021, 22, 4159.	1.8	41
104	Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. Cancers, 2021, 13, 3083.	1.7	9
105	Imaging Assessment of Tumor Response in the Era of Immunotherapy. Diagnostics, 2021, 11, 1041.	1.3	3
106	The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. Cancers, 2021, 13, 3117.	1.7	17
107	Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST. Japanese Journal of Radiology, 2022, 40, 75-85.	1.0	12
108	18F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centers. Annals of Nuclear Medicine, 2021, 35, 1253-1263.	1.2	5
109	CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of ⁸⁹Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody. Journal of Nuclear Medicine, 2021, , jnumed.121.262485.	2.8	49
110	Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study. EJNMMI Research, 2021, 11, 89.	1.1	15
111	Update on Molecular Imaging and Precision Medicine in Lung Cancer. Radiologic Clinics of North America, 2021, 59, 693-703.	0.9	5
112	Immune PET Imaging. Radiologic Clinics of North America, 2021, 59, 875-886.	0.9	2

#	Article	IF	Citations
113	Precision Nuclear Medicine. Radiologic Clinics of North America, 2021, 59, 755-772.	0.9	3
114	Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers. Cancer Imaging, 2021, 21, 11.	1.2	21
115	Molecular and Functional Imaging in Oncology Therapy Response. Medical Radiology, 2020, , 255-272.	0.0	2
116	Evaluating response to immunotherapy with 18F-FDG PET/CT: where do we stand?. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1019-1021.	3.3	14
117	Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 21-39.	3.3	96
118	Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1932-1943.	3.3	17
119	18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2031-2037.	3.3	27
120	Influence on [18F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor. EJNMMI Research, 2020, 10, 24.	1.1	10
121	PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. European Radiology Experimental, 2020, 4, 63.	1.7	38
122	Outcome Prediction and Evaluation by Imaging the Key Elements of Therapeutic Responses to Cancer Immunotherapies Using PET. Current Pharmaceutical Design, 2020, 26, 675-687.	0.9	3
123	The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art. Current Radiopharmaceuticals, 2020, 13, 24-31.	0.3	6
124	Response assessment of bone metastatic disease: seeing the forest for the trees RECIST, PERCIST, iRECIST, and PCWG-2. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 150-158.	0.4	7
125	Update on tumor metabolism and patterns of response to immunotherapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 175-185.	0.4	8
126	[¹⁸F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab. Radiology and Oncology, 2020, 54, 285-294.	0.6	48
127	Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of ¹⁸F-FDG PET/CT. Journal of Nuclear Medicine, 2020, 61, 943-950.	2.8	39
128	Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 2021, 62, 6-14.	2.8	13
129	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers, 2020, 12, 1303.	1.7	6
130	Imaging Melanoma. , 2018, , 1-25.		0

#	Article	IF	Citations
131	Diagnosis of Stage IV Melanoma. , 2019, , 1-47.		1
132	Pitfalls and Immune-Related Adverse Events. , 2020, , 101-115.		3
133	Melanoma: 18F-FDG PET/CT for Response Assessment of Melanoma Following Immunotherapy. , 2020, , 55-65.		3
134	Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma. , 2020, , 57-71.		0
136	F-18 FDG PET Tests in Skin Cancer Including Malignant Melanoma. , 2021, , 119-134.		0
137	Response evaluation after immunotherapy in NSCLC. Medicine (United States), 2020, 99, e23815.	0.4	8
138	Diagnosis of Stage IV Melanoma. , 2020, , 997-1043.		0
139	Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. Journal of Clinical Medicine, 2021, 10, 5160.	1.0	20
140	Halo artifacts of indwelling urinary catheter by inaccurate scatter correction in 18F-FDG PET/CT imaging: incidence, mechanism, and solutions. EJNMMI Physics, 2020, 7, 66.	1.3	4
141	Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods.. Journal of Nuclear Medicine, 2021, 62, jnumed.120.254508.	2.8	19
142	Quantitative Imaging in Oncologic PET. , 2021, , 1-100.		0
143	Introduction on Nuclear Medicine and Immunology. , 2022, , 1-13.		1
144	Radioimaging of Activated T Cells in Preclinical and Clinical Cancer Investigations. , 2022, , 61-101.		0
145	18F FDG IMAGING â€“ RESPONSE CRITERIA IN TUMORS. European Journal of Radiology, 2021, 147, 110054.	1.2	3
146	Prognostic value of 2-[18F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy. European Journal of Radiology, 2022, 146, 110107.	1.2	8
148	Molecular response assessment with immune adaptive positron emission tomography response criteria in solid tumors in lung cancer patients treated with nivolumab: Is it better than immune response evaluation criteria in solid tumors?. World Journal of Nuclear Medicine, 2022, .	0.3	0
149	Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy. Frontiers in Oncology, 2021, 11, 786089.	1.3	2
150	Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma. Cancer Imaging, 2022, 22, 11.	1.2	2

#	Article	IF	Citations
151	Potentials of Non-Invasive 18F-FDG PET/CT in Immunotherapy Prediction for Nonâ€“Small Cell Lung Cancer. Frontiers in Genetics, 2021, 12, 810011.	1.1	10
153	Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma. Journal of Nuclear Medicine, 2022, , jnumed.121.263151.	2.8	0
154	Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. , 2022, 10, e003635.		42
155	Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?. World Journal of Nuclear Medicine, 2022, 21, 34-43.	0.3	0
156	Use of Fluoro-[¹⁸F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. JAMA Otolaryngology - Head and Neck Surgery, 2022, 148, 268.	1.2	3
157	Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2323-2341.	3.3	48
158	Role of 18F-FDG PET/CT in the assessment of therapy response and clinical outcome in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors or immunotherapy. Nuclear Medicine Communications, 2022, 43, 701-709.	0.5	2
159	Imaging immunity in patients with cancer using positron emission tomography. Npj Precision Oncology, 2022, 6, 24.	2.3	13
160	Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1857-1869.	3.3	9
162	Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 66, .	0.4	7
163	FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. Seminars in Nuclear Medicine, 2022, 52, 707-719.	2.5	10
164	Radiopharmaceuticals as Novel Immune System Tracers. Advances in Radiation Oncology, 2022, , 100936.	0.6	1
165	A Decade of Success in Melanoma Immunotherapy and Targeted Therapy: What Every Radiologist Should Know. Journal of Computer Assisted Tomography, 2022, 46, 621-632.	0.5	2
166	Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction. Critical Reviews in Oncology/Hematology, 2022, 176, 103746.	2.0	1
167	Prognostic impact of an integrative analysis of [18F]FDG PET parameters and infiltrating immune cell scores in lung adenocarcinoma. EJNMMI Research, 2022, 12, .	1.1	0
168	¹⁸F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. Radiology, 2022, 304, 246-264.	3.6	14
169	Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab. Frontiers in Immunology, 0, 13, .	2.2	2
171	18F-FDG PET/CT in the clinical-diagnostic workup of patients treated with immunotherapy: when and how?. Clinical and Translational Imaging, 2022, 10, 325-329.	1.1	2

#	Article	IF	Citations
172	Comparing [18F]FDG PET/CT response criteria in melanoma and lung cancer patients treated with immunotherapy: a systematic review. Clinical and Translational Imaging, 2022, 10, 643-661.	1.1	5
173	Tumor response assessment on imaging following immunotherapy. Frontiers in Oncology, 0, 12, .	1.3	12
174	The radiological appearances of lung cancer treated with immunotherapy. British Journal of Radiology, 2023, 96, .	1.0	1
176	Modern aspects of immunotherapy with checkpoint inhibitors in melanoma. Medical Alphabet, 2022, , 35-40.	0.0	2
177	Imaging endpoints for clinical trial use: a RECIST perspective. , 2022, 10, e005092.		2
179	Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors. Cancer Imaging, 2022, 22, .	1.2	4
180	The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors. Frontiers in Immunology, 0, 13, .	2.2	1
181	Hyperpolarized 13C-Pyruvate to Assess Response to Anti-PD1 Immune Checkpoint Inhibition in YUMMER 1.7 Melanoma Xenografts. International Journal of Molecular Sciences, 2023, 24, 2499.	1.8	2
182	[18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors. , 2023, , 1-40.		0
183	ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors. Cancers, 2023, 15, 878.	1.7	6
184	Imaging the immune cell in immunotherapy. , 2023, , 197-238.		1
185	Predictive value of 18F-FDG PET/CT for evaluating the response to hypofractionated radiotherapy combined with PD-1 blockade in non-small cell lung cancer. Frontiers in Immunology, 0, 14, .	2.2	0
186	Standardized classification schemes in reporting oncologic PET/CT. Frontiers in Medicine, 0, 9, .	1.2	2
187	Novelties from the Joint EANM/SNMMI/ANZSNM Guidelines on Immunotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2023, 38, 211-215.	0.7	2
188	Imageâ€based response assessment during immunotherapy in skin cancer. JDDG - Journal of the German Society of Dermatology, 2023, 21, 107-114.	0.4	0
189	BildgestÃ¼tzte Beurteilung des Ansprechens auf Immuntherapien bei Hauttumoren. JDDG - Journal of the German Society of Dermatology, 2023, 21, 107-115.	0.4	0
190	PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score. Life, 2023, 13, 611.	1.1	4
191	Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. Lancet Oncology, The, 2023, 24, e133-e143.	5.1	6

#	Article	IF	Citations
192	FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab. Radiology, 2023, 307, .	3.6	6
193	Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial. Journal of Thoracic Oncology, 2023, 18, 780-791.	0.5	4
194	[18F]FDG PET/CT in the Evaluation of Melanoma Patients Treated with Immunotherapy. Diagnostics, 2023, 13, 978.	1.3	4
195	Molecular imaging for cancer immunotherapy. , 2023, 1, 3-17.		4
199	[18F]FDG PET/CT criteria for treatment response assessment: EORTC and beyond. Clinical and Translational Imaging, 2023, 11, 421-437.	1.1	2
206	The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1. Japanese Journal of Radiology, 0, , .	1.0	0